News

Researchers at the Ospedale San Raffaele (OSR) Scientific Institute in Milan, Italy, supported by the Charcot-Marie-Tooth Association (CMTA) and its Strategy To Accelerate Research (STAR), have made encouraging progress in developing a potential treatment for CMT1B. This groundbreaking work, led ...

The Charcot-Marie-Tooth Association (CMTA), through its Strategy To Accelerate Research (STAR) initiative, is proud to support groundbreaking research that seeks to deepen our understanding of CMT2A and CMT2F, two axonal forms of Charcot-Marie-Tooth disease (CMT). With CMTA funding support of ...

#LetsBeatCMT is a social media initiative during CMT Awareness Month to encourage the Charcot-Marie-Tooth disease community to share their CMT experiences throughout September. Post your videos and photos on social media using #LetsBeatCMT to educate the world about CMT’s impact and ...

The Charcot-Marie-Tooth Association (CMTA) is pleased to share exciting news from our CMTA-STAR Alliance Partner, Actio Biosciences. The company has received both orphan drug designation (ODD) and rare pediatric disease designation (RPDD) designation from the FDA for ABS-0871, a TRPV4 ...

The Charcot-Marie-Tooth Association (CMTA) is pleased to share exciting news from our CMTA-STAR Alliance Partner, Applied Therapeutics. The company plans to submit a New Drug Application (NDA) to the FDA for govorestat to treat CMT-SORD (aka SORD Deficiency), a significant ...